Closed · W81XWH-22-RCRP-IDA · CFDA 12.420 · Discretionary
DoD Rare Cancers, Idea Development Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- October 6, 2022
- Close date
- 15
- Expected awards
The verdict
DoD Rare Cancers, Idea Development Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 15 expected awards. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 15
- expected awards
- 12.420
- CFDA program
Opportunity snapshot. This Grants.gov announcement - DoD Rare Cancers, Idea Development Award - is cataloged under number W81XWH-22-RCRP-IDA and tied to CFDA assistance listing 12.420, posted by Defense Health Agency Contracting Activity - DHACA. Grants.gov currently shows the opportunity as closed, first posted on April 20, 2022 and last updated on August 2, 2022. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. The agency has projected $8.4 million in total estimated funding for this announcement. It expects to issue 15 awards. If the agency funds the expected 15 awards from the $8.4 million estimated pool, the average award works out to roughly $560,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on October 6, 2022. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
October 6, 2022
Posted
April 20, 2022
Est. Total Funding
$8,400,000
Expected Awards
15
Instrument
Grant
Description
The FY22 RCRP Idea Development Award promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from rare cancers. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.Preliminary data with disease-specific rationale (may include correlatives studies to ongoing clinical research) to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of the proposed rare cancer type(s)/subtype(s) under study. Key elements of the Idea Development Award are as follows:• Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities in the following ways: in concept or question, research methods or technologies, adaptations of existing methods or technologies, or other ways. Research that is likely to yield only an incremental advance is not considered innovative.• Impact: Research that has high potential impact may lead to major advancements and greatly improve outcomes for people with rare cancers.
Eligibility
Grants.gov lists this opportunity under eligibility category code 99. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |